[go: up one dir, main page]

BE2015C025I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C025I2
BE2015C025I2 BE2015C025C BE2015C025C BE2015C025I2 BE 2015C025 I2 BE2015C025 I2 BE 2015C025I2 BE 2015C025 C BE2015C025 C BE 2015C025C BE 2015C025 C BE2015C025 C BE 2015C025C BE 2015C025 I2 BE2015C025 I2 BE 2015C025I2
Authority
BE
Belgium
Application number
BE2015C025C
Other languages
French (fr)
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of BE2015C025I2 publication Critical patent/BE2015C025I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BE2015C025C 2003-04-11 2015-04-20 BE2015C025I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46198803P 2003-04-11 2003-04-11
PCT/US2004/011106 WO2004091502A2 (en) 2003-04-11 2004-04-09 1,2,4-oxadiazole benzoic acid compounds

Publications (1)

Publication Number Publication Date
BE2015C025I2 true BE2015C025I2 (en) 2023-08-09

Family

ID=33299886

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C025C BE2015C025I2 (en) 2003-04-11 2015-04-20

Country Status (29)

Country Link
US (17) US6992096B2 (en)
EP (9) EP3889142B1 (en)
JP (2) JP4851933B2 (en)
KR (1) KR101134188B1 (en)
CN (2) CN104056278B (en)
AU (1) AU2004229487B9 (en)
BE (1) BE2015C025I2 (en)
BR (1) BRPI0409319B8 (en)
CA (1) CA2521992C (en)
CR (1) CR8086A (en)
CY (7) CY1115870T1 (en)
DK (7) DK2910551T3 (en)
EA (1) EA009120B1 (en)
ES (7) ES2679108T3 (en)
FR (1) FR15C0030I2 (en)
HU (7) HUE039026T2 (en)
IL (2) IL171343A (en)
LU (1) LU92698I2 (en)
MA (1) MA27802A1 (en)
MX (1) MXPA05010747A (en)
NO (2) NO332843B1 (en)
NZ (1) NZ543263A (en)
PL (7) PL1618098T3 (en)
PT (7) PT3889142T (en)
SI (7) SI1618098T1 (en)
TR (1) TR201706226T4 (en)
UA (1) UA84420C2 (en)
WO (1) WO2004091502A2 (en)
ZA (1) ZA200508298B (en)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2004001010A2 (en) * 2002-06-21 2003-12-31 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
WO2004010106A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
EP3889142B1 (en) * 2003-04-11 2022-06-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
KR20070067165A (en) 2004-10-13 2007-06-27 피티씨 테라퓨틱스, 인크. Nonsense Mutation-Inhibiting Compound, and Method of Use thereof
AU2012238226B2 (en) * 2005-04-08 2015-05-14 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
CN100378084C (en) * 2005-08-01 2008-04-02 安徽大学 2,5-diaryl substituent-1,3,4-oxadiazole derivatives and their synthesis methods and uses
ES2436109T3 (en) * 2006-02-09 2013-12-27 Belrose Pharma Inc. Polymeric 7-ethyl-10-hydroxycamptothecin polymer conjugates for the treatment of breast cancer, colorectal cancer, pancreas, ovarian and lung cancer
IN2014CN04406A (en) * 2006-03-30 2015-09-04 Ptc Therapeutics Inc
JP2009532453A (en) * 2006-04-06 2009-09-10 プロシディオン・リミテッド Heterocyclic GPCR agonist
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
IN2014KN02423A (en) 2006-04-07 2015-05-01 Vertex Pharma
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2007130499A2 (en) * 2006-05-01 2007-11-15 Virobay, Inc. Antiviral agents
MX2009002439A (en) * 2006-09-08 2009-03-27 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids.
EP2068871B1 (en) 2006-09-25 2013-12-25 PTC Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
SG185979A1 (en) * 2006-09-25 2012-12-28 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
AU2016262645B2 (en) * 2006-10-12 2018-05-17 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
AU2013219243B2 (en) * 2006-10-12 2016-09-08 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
DK2073805T3 (en) * 2006-10-12 2015-06-15 Ptc Therapeutics Inc Methods of Dosing an Orally Active 1,2,4-Oxadiazole for Therapy for Suppression of Nonsense Mutation
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
KR20090095648A (en) * 2006-12-15 2009-09-09 아보트 러보러터리즈 Novel oxadiazole compounds
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
UY30846A1 (en) 2006-12-30 2008-07-31 Abbott Gmbh & Amp OXINDOL DERIVATIVES REPLACED, MEDICINES THAT UNDERSTAND AND USE THEMSELVES
JP2010523579A (en) * 2007-04-02 2010-07-15 インスティテュート フォア ワンワールド ヘルス CFTR inhibitor compounds and their use
MX2009014001A (en) * 2007-06-22 2010-01-28 Hoffmann La Roche Isoxazole-imidazole derivatives.
JP2010534231A (en) * 2007-07-23 2010-11-04 ビオマリン アイジーエー リミテッド Compounds for the treatment of Duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
ES2617957T3 (en) 2007-08-03 2017-06-20 Summit (Oxford) Limited Pharmacological combinations for the treatment of Duchenne muscular dystrophy
PL2786992T3 (en) 2007-08-13 2018-04-30 Monsanto Technology Llc Compositions and methods for controlling nematodes
KR20100083814A (en) 2007-10-04 2010-07-22 메르크 세로노 에스. 에이. Oxadiazole diaryl compounds
KR20100075608A (en) 2007-10-04 2010-07-02 메르크 세로노 에스. 에이. Oxadiazole derivatives
US8551534B2 (en) * 2007-10-10 2013-10-08 Parion Sciences, Inc. Inhaled hypertonic saline delivered by a heated nasal cannula
WO2009064959A1 (en) 2007-11-16 2009-05-22 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
JP5595926B2 (en) * 2007-12-07 2014-09-24 アボット ゲーエムベーハー ウント カンパニー カーゲー 5-Halogen-substituted oxindole derivatives and their use in the treatment of vasopressin-dependent diseases
WO2010009775A1 (en) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
CA2707671C (en) * 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
JP5701607B2 (en) * 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Amidomethyl-substituted oxindole derivatives and their use in the treatment of vasopressin-dependent diseases
PT2225230T (en) 2007-12-07 2016-12-07 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
KR20100110834A (en) * 2007-12-21 2010-10-13 메르크 세로노 에스. 에이. Triazole oxadiazoles derivatives
BRPI0821327A2 (en) * 2007-12-25 2015-06-16 Kissei Pharmaceutical Catechol derivative, pharmaceutical composition containing same, use of catechol derivative, and use of pharmaceutical composition
WO2009100438A2 (en) * 2008-02-07 2009-08-13 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
EP2271621B1 (en) 2008-03-31 2013-11-20 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as cftr modulators
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131956A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazole derivatives
WO2009131954A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
MX339144B (en) * 2008-06-09 2016-05-13 Univ Muenchen Ludwig Maximilians New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases.
CA2729212C (en) * 2008-06-24 2014-04-01 Irm Llc Compounds and methods for modulating g protein-coupled receptors
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES
HUE025314T2 (en) 2009-02-10 2016-02-29 Monsanto Technology Llc Compositions and methods for controlling nematodes
JP5620129B2 (en) 2009-03-19 2014-11-05 富士フイルム株式会社 Optical film, retardation plate, elliptically polarizing plate, liquid crystal display device, and compound
RU2398770C1 (en) * 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Tritium-labelled 3-[5-(2-flurophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2251437B1 (en) 2009-05-13 2013-12-04 Hannelore Breitenbach-Koller Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
AR076984A1 (en) 2009-06-08 2011-07-20 Merck Serono Sa DERIVATIVES OF PIRAZOL OXADIAZOL
US9849146B2 (en) * 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
RU2604459C2 (en) * 2009-08-05 2016-12-10 Интернэшнл Пэйпа Кампани Additive for dry sheet of loose cellulose
RS57070B1 (en) 2009-11-13 2018-06-29 Celgene Int Ii Sarl Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
MY161854A (en) 2009-11-13 2017-05-15 Receptos Inc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
NZ602665A (en) 2010-03-25 2014-10-31 Vertex Pharma Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP2555754B1 (en) 2010-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
HRP20211752T1 (en) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
KR20130056244A (en) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CN103189060A (en) * 2010-08-05 2013-07-03 里尔法律与医疗卫生第二大学 Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
CA2808501A1 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
ES2758841T3 (en) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Selective heterocyclic sphingosine-1-phosphate receptor modulators
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US8778383B2 (en) 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
WO2012170371A1 (en) * 2011-06-10 2012-12-13 N30 Pharmaceuticals, Llc Compounds as s-nitrosoglutathione reductase inhibitors
AR086745A1 (en) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-DIAMINO-6-CHLORINE-N- (N- (4- (4- (2- (HEXIL (2,3,4,5,6-PENTAHYDROXIHEXIL)) AMINO) ETOXI) PHENYL) BUTIL) CARBAMIMIDOIL) PIRAZINA -2-CARBOXAMIDE
KR101314488B1 (en) * 2011-09-08 2013-10-07 중앙대학교 산학협력단 Novel oxadiazole derivatives for differentiation of neural stem cells and medical use thereof
LT2776427T (en) 2011-11-08 2017-04-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
UA114619C2 (en) 2012-01-25 2017-07-10 Вертекс Фармасьютікалз Інкорпорейтед Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2013142346A1 (en) * 2012-03-23 2013-09-26 The Regents Of The University Of California Premature-termination-codons readthrough compounds
AU2013267504B2 (en) 2012-05-29 2017-11-02 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
CA2876215A1 (en) 2012-07-02 2014-01-09 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
HK1209318A1 (en) 2012-07-16 2016-04-01 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
BR112015009913B1 (en) 2012-11-02 2023-04-11 Vertex Pharmaceuticals Incorporated TABLET COMPRISING CRYSTALLINE COMPOUND AND SOLID DISPERSION OF SUBSTANTIALLY AMORPHOUS COMPOUND, ITS PREPARATION PROCESS, KIT AND METHOD OF PREPARATION OF A GRANULE COMPRISING CRYSTALLINE COMPOUND AND SOLID DISPERSION OF SUBSTANTIALLY AMORPHOUS COMPOUND
EP2931282B1 (en) 2012-12-13 2018-10-31 Novartis AG Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
CN108658876A (en) 2012-12-17 2018-10-16 帕里昂科学公司 The chloro- N- of 3,5- diamino -6- (N- (4- phenyl butyls) carbonamidine base) pyrazine -2- benzamide compounds
HUE032891T2 (en) 2012-12-17 2017-11-28 Parion Sciences Inc Chlorpyrazine Carboxamide Derivatives For Insufficient Mucosal Hydration Treatment
ES2674665T3 (en) 2012-12-17 2018-07-03 Parion Sciences, Inc. 3,5-Diamino-6-Chloro-N- (N- (4-phenylbutyl) carbamimidoyl) -pyrazine-2-carboxamide compounds
CN106455571A (en) * 2014-03-06 2017-02-22 Ptc医疗公司 Pharmaceutical compositions and salts of 1,2,4-oxadiazolebenzoic acid
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
ES2885181T3 (en) 2014-04-15 2021-12-13 Vertex Pharma Pharmaceutical compositions for the treatment of diseases mediated by the transmembrane conductance regulator of cystic fibrosis
ES2743183T3 (en) 2014-06-03 2020-02-18 Novartis Ag Pyridopyrimidinodione derivatives as suppressors of terminator mutations
MX374245B (en) 2014-06-03 2025-03-05 Novartis Ag NAPHTHYRIDINEDIONE DERIVATIVES.
EP3152208B1 (en) 2014-06-03 2019-05-08 Novartis AG Pyrimido[4,5-b]quinoline-4,5(3h,10h)-dione derivatives as suppressors of non-sens mutations
CN105461650B (en) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 Solvate of Yi Zhong oxadiazole compounds and preparation method thereof
WO2016057572A1 (en) 2014-10-06 2016-04-14 Mark Thomas Miller Modulators of cystic fibrosis transmembrane conductance regulator
CN104292180A (en) * 2014-10-12 2015-01-21 湖南华腾制药有限公司 Preparation method of oxadiazole derivative
US10174012B2 (en) 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
WO2016073545A1 (en) * 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
BR112017012588B8 (en) * 2014-12-17 2024-02-15 King S College London Bicyclic heteroaryl-heteroaryl compounds of benzoic acid, their uses, pharmaceutical compositions, methods of preparation thereof and methods for causing or promoting neurite outgrowth, neurite outgrowth and/or neurite regeneration and for activating the retinoic acid beta receptor
CN106316885B (en) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 A kind of preparation method of 3- [5- (2- fluorophenyl) -1,2,4- oxadiazoles -3- base] benzoic acid
TW201729807A (en) * 2015-10-30 2017-09-01 Ｐｔｃ治療公司 Methods for treating epilepsy
PT3377476T (en) * 2015-11-16 2022-12-29 Ptc Therapeutics Inc Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
JP2019505579A (en) 2015-12-23 2019-02-28 ムーンショット ファーマ エルエルシー Methods for inducing an immune response
TW201808922A (en) * 2016-06-20 2018-03-16 台灣神隆股份有限公司 Process for preparing ataluren and its intermediates
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
CN106279057B (en) * 2016-08-15 2022-04-15 广州明药科技有限公司 Synthetic method of Ataluren
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
WO2018050706A1 (en) 2016-09-13 2018-03-22 Marco Cipolli Method of treatment of shwachman-diamond syndrome
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
EP3641752A4 (en) 2017-06-22 2021-03-17 Moonshot Pharma LLC Methods for treating cancer with compositions comprising amlexanox and immune modulators
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
WO2020078894A1 (en) 2018-10-15 2020-04-23 Academisch Medisch Centrum Oncotherapeutic combinations
KR102658031B1 (en) 2018-12-27 2024-04-18 제이투에이치바이오텍 (주) Compounds for treating or preventing muscular dystrophy and medical uses thereof
EA202192767A1 (en) * 2019-04-10 2021-12-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. METHOD FOR THE TREATMENT OF NONSENSE MUTATION-MEDIATED DUSCHENNE MUSCULAR DYSTROPHY IN PEDIATRIC PATIENTS
CN110987847B (en) * 2019-12-11 2021-02-19 苏州今蓝纳米科技有限公司 Application of 1,3, 4-oxadiazole derivative in acid detection and data encryption and storage
CN111675672A (en) * 2020-05-12 2020-09-18 石家庄市度智医药科技有限公司 Method for preparing astallurens
CN113045510B (en) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 Preparation method of atralone
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
CN116217508B (en) * 2022-12-15 2024-12-17 浙江工业大学 Oxadiazole compound for protecting beta cells to treat type II diabetes, and preparation method and application thereof
US11932632B1 (en) 2023-10-13 2024-03-19 King Faisal University N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound
US11958814B1 (en) 2023-11-02 2024-04-16 King Faisal University 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound
CN119638642A (en) * 2023-12-12 2025-03-18 暨南大学 Bicyclic compounds, pharmaceutical composition and application thereof
WO2025243250A1 (en) * 2024-05-23 2025-11-27 Biophore India Pharmaceuticals Pvt. Ltd. A process for the preparation of 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (en) 1962-04-17
US3325446A (en) 1964-04-17 1967-06-13 Allied Chem Stabilized halogen-containing olefin polymer compositions and stabilizers therefor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
JPS51143669A (en) 1975-06-06 1976-12-10 Takeda Chem Ind Ltd A process for preparing 1,2,4- oxadiazole derivatives
US4016170A (en) * 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4166732A (en) 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4165910A (en) * 1977-10-25 1979-08-28 Bunker Ramo Corporation Electrical connector
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
EP0036711B1 (en) 1980-03-22 1985-12-04 Fbc Limited Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (en) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4320801A1 (en) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenyl-substituted 1,2,4-triazoles and 1,2,4-oxadiazoles, their use as pharmaceutical agents and pharmaceutical compositions containing them
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US6071700A (en) 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
JP3585127B2 (en) 1995-03-14 2004-11-04 シーメンス アクチエンゲゼルシヤフト Ultrasonic spray system
JP3142577B2 (en) 1995-03-14 2001-03-07 シーメンス アクチエンゲゼルシヤフト Removable precision metering unit
TR199800414T1 (en) 1995-09-07 1998-05-21 Novartis Ag Modified phosphinic compounds and their use as drugs.
WO1997039745A1 (en) 1996-04-19 1997-10-30 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
WO1997041105A1 (en) * 1996-04-26 1997-11-06 Nippon Soda Co., Ltd. Novel heterocycle-substituted benzene derivatives and herbicides
DE19620041A1 (en) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhesion receptor antagonists
EP0906310A4 (en) 1996-06-07 1999-09-01 Merck & Co Inc OXADIAZOLE BENZENESULFONAMIDES AS AGONISTS -g (b) 3? SELECTIVE FOR THE TREATMENT OF DIABETES AND OBESITY
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
DE19626318A1 (en) 1996-07-01 1998-01-08 Basf Ag Dye mixtures containing polyazo dyes
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
ES2329739T3 (en) 1997-04-07 2009-11-30 Georgetown University COCAINA ANALOGS
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
AU9647998A (en) * 1997-10-27 1999-05-17 Nippon Soda Co., Ltd. Novel benzoylpyrazole derivatives and herbicides
NZ506289A (en) 1998-03-16 2004-12-24 Nektar Therapeutics Aerosolized active agent delivery to the lungs at a flow rate of less than 17 liters per minute
CA2329712A1 (en) 1998-04-23 1999-10-28 Cortech Inc. Cysteine protease inhibitors
US6605607B1 (en) 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
DE69914931T2 (en) 1998-10-09 2004-12-16 Janssen Pharmaceutica N.V. 4,5-DEHYDROISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE
EP1126833A4 (en) 1998-10-29 2004-09-08 Trega Biosciences Inc Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
HK1043536A1 (en) 1998-12-23 2002-09-20 Smithkline Beecham Corporation Protease inhibitors
WO2000058304A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
WO2000058280A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
WO2000058278A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. β-AMINO ACID DERIVATIVES
CN1356977A (en) 1999-05-17 2002-07-03 诺沃挪第克公司 Glucagon antagonists/inverse agonists
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (en) 1999-08-12 2001-09-11 Japan Tobacco Inc Pyrrolidine derivative or piperidine derivative and its medicinal use
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
JP2003528107A (en) 2000-03-22 2003-09-24 メルク フロスト カナダ アンド カンパニー Sulfur-substituted aryldifluoromethylphosphonic acids as PTP-1B inhibitors
WO2001083464A1 (en) * 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) * 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
AR033525A1 (en) 2000-05-22 2003-12-26 Aventis Pharma Ltd REPLACED ARILMETILAMINS, PHARMACEUTICAL COMPOSITIONS, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
CN1328143A (en) 2000-06-12 2001-12-26 上海博德基因开发有限公司 Polypeptide-human methylation-DNA-protein-cysteine methyltransferase 13 and polynucleotide for coding it
JP2002105073A (en) 2000-09-27 2002-04-10 Shionogi & Co Ltd New matrix metalloprotease inhibitor
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
BR0209054A (en) 2001-04-19 2004-04-20 Bayer Ag Arylsulfonamides as antiviral agents
RU2003138074A (en) 2001-06-08 2005-02-20 Цитови Инк. (US) SUBSTITUTED 3-Aryl-5-Aryl- [1,2,4] -Oxadiazoles and their analogues as caspase activators and apoptosis inducers, as well as their use
JP2003081832A (en) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd Function regulator for retinoid relative receptor
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
NZ538339A (en) 2002-08-09 2007-01-26 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
CA2495179A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP1622872A1 (en) 2003-03-28 2006-02-08 Pfizer Products Inc. 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
EP3889142B1 (en) * 2003-04-11 2022-06-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
KR20070067165A (en) 2004-10-13 2007-06-27 피티씨 테라퓨틱스, 인크. Nonsense Mutation-Inhibiting Compound, and Method of Use thereof
CA2603402C (en) * 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
IN2014CN04406A (en) 2006-03-30 2015-09-04 Ptc Therapeutics Inc
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
MX2009002439A (en) 2006-09-08 2009-03-27 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids.
SG185979A1 (en) 2006-09-25 2012-12-28 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
DK2073805T3 (en) 2006-10-12 2015-06-15 Ptc Therapeutics Inc Methods of Dosing an Orally Active 1,2,4-Oxadiazole for Therapy for Suppression of Nonsense Mutation
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2009023509A2 (en) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
KR20100075608A (en) 2007-10-04 2010-07-02 메르크 세로노 에스. 에이. Oxadiazole derivatives
ES2639852T3 (en) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Means and methods to counteract muscle disorders
ES2436781T3 (en) 2007-12-17 2014-01-07 The Regents Of The University Of Michigan Compositions and procedures for treatment and prevention of skeletal muscle deficiencies
CA2729212C (en) 2008-06-24 2014-04-01 Irm Llc Compounds and methods for modulating g protein-coupled receptors
HUE038428T2 (en) 2008-10-07 2018-10-29 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
RU2398770C1 (en) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Tritium-labelled 3-[5-(2-flurophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid

Also Published As

Publication number Publication date
AU2004229487A1 (en) 2004-10-28
SI3103800T1 (en) 2018-10-30
FR15C0030I2 (en) 2015-07-24
PL3549936T3 (en) 2021-11-08
EP3632902B1 (en) 2021-07-14
SI3632902T1 (en) 2022-01-31
CR8086A (en) 2006-12-19
NO20055314D0 (en) 2005-11-10
CN104056278A (en) 2014-09-24
EP4101846A1 (en) 2022-12-14
US6992096B2 (en) 2006-01-31
IL225161A (en) 2014-03-31
EP3103800A1 (en) 2016-12-14
PL3103800T3 (en) 2018-11-30
NO20055314L (en) 2006-01-04
PL1618098T3 (en) 2015-04-30
US9861617B2 (en) 2018-01-09
PT1618098E (en) 2015-02-10
JP2006522826A (en) 2006-10-05
KR20060009838A (en) 2006-02-01
CY1115870T1 (en) 2016-06-22
US7772259B2 (en) 2010-08-10
EA009120B1 (en) 2007-10-26
PT3889142T (en) 2022-08-22
ES2770035T3 (en) 2020-06-30
EP3345895A1 (en) 2018-07-11
ES2881198T3 (en) 2021-11-29
PL2910551T3 (en) 2017-09-29
US20150148346A1 (en) 2015-05-28
EP1618098B1 (en) 2014-11-19
US20100168109A1 (en) 2010-07-01
HUS1500021I1 (en) 2017-04-28
SI3345895T1 (en) 2020-03-31
CY2015017I1 (en) 2016-06-22
EP3549936B1 (en) 2021-06-02
US20100216851A1 (en) 2010-08-26
HUE047569T2 (en) 2020-04-28
CY1125544T1 (en) 2024-09-20
NZ543263A (en) 2008-12-24
DK1618098T3 (en) 2015-01-12
UA84420C2 (en) 2008-10-27
SI2910551T1 (en) 2017-07-31
DK3889142T3 (en) 2022-09-12
US20060148864A1 (en) 2006-07-06
US7304080B2 (en) 2007-12-04
PT3345895T (en) 2020-01-29
MA27802A1 (en) 2006-03-01
KR101134188B1 (en) 2012-04-12
US8227494B2 (en) 2012-07-24
EP2910551B1 (en) 2017-02-15
AU2004229487B9 (en) 2010-06-10
SI3889142T1 (en) 2022-10-28
CY1124464T1 (en) 2022-07-22
EP1618098A2 (en) 2006-01-25
CN104056278B (en) 2017-01-18
PT3549936T (en) 2021-07-14
CN1802360B (en) 2014-05-07
US8486982B2 (en) 2013-07-16
US20130289007A1 (en) 2013-10-31
EP3889142B1 (en) 2022-06-15
US20070161687A1 (en) 2007-07-12
US9205088B2 (en) 2015-12-08
PT3103800T (en) 2018-07-27
US20180092887A1 (en) 2018-04-05
JP2011251981A (en) 2011-12-15
IL171343A (en) 2013-06-27
ES2624610T3 (en) 2017-07-17
SI3549936T1 (en) 2021-09-30
US20140301978A1 (en) 2014-10-09
US8796322B2 (en) 2014-08-05
US8975287B2 (en) 2015-03-10
US20120277234A1 (en) 2012-11-01
US20110311486A1 (en) 2011-12-22
EP2910551A1 (en) 2015-08-26
HK1214253A1 (en) 2016-07-22
DK3103800T3 (en) 2018-07-30
CA2521992A1 (en) 2004-10-28
US20040204461A1 (en) 2004-10-14
HUE059464T2 (en) 2022-11-28
US8163782B2 (en) 2012-04-24
HK1093979A1 (en) 2007-03-16
US20060148863A1 (en) 2006-07-06
DK2910551T3 (en) 2017-05-15
US7683082B2 (en) 2010-03-23
JP5436500B2 (en) 2014-03-05
US20100121070A1 (en) 2010-05-13
US8299105B2 (en) 2012-10-30
DK3549936T3 (en) 2021-07-12
PL3632902T3 (en) 2021-12-20
US8017636B2 (en) 2011-09-13
SI1618098T1 (en) 2015-04-30
ES2679108T3 (en) 2018-08-22
CY1120446T1 (en) 2019-07-10
US7202262B2 (en) 2007-04-10
HUE039026T2 (en) 2018-12-28
HUE055056T2 (en) 2021-10-28
PT3632902T (en) 2021-09-15
CY1122659T1 (en) 2020-10-14
US20060035943A1 (en) 2006-02-16
CY1119001T1 (en) 2018-01-10
PL3889142T3 (en) 2022-09-26
WO2004091502A2 (en) 2004-10-28
HK1257517A1 (en) 2019-10-25
NO2015002I1 (en) 2015-02-16
WO2004091502A8 (en) 2005-11-24
EP3889142A1 (en) 2021-10-06
EP3549936A1 (en) 2019-10-09
EA200501601A1 (en) 2006-06-30
TR201706226T4 (en) 2018-06-21
EP3103800B1 (en) 2018-06-13
BRPI0409319A (en) 2006-04-25
HUE031794T2 (en) 2017-08-28
DK3345895T3 (en) 2020-02-03
AU2004229487B2 (en) 2010-05-20
EP3178816A1 (en) 2017-06-14
NO2015002I2 (en) 2015-02-03
JP4851933B2 (en) 2012-01-11
US8129540B2 (en) 2012-03-06
BRPI0409319B1 (en) 2019-11-12
PT2910551T (en) 2017-05-22
PL3345895T3 (en) 2020-05-18
ES2528195T3 (en) 2015-02-05
MXPA05010747A (en) 2006-05-25
EP3632902A1 (en) 2020-04-08
NO332843B1 (en) 2013-01-21
ES2887054T3 (en) 2021-12-21
EP1618098A4 (en) 2008-07-16
US10071081B2 (en) 2018-09-11
US20050164973A1 (en) 2005-07-28
BRPI0409319B8 (en) 2021-05-25
HK1202254A1 (en) 2015-09-25
CN1802360A (en) 2006-07-12
FR15C0030I1 (en) 2015-05-22
DK3632902T3 (en) 2021-09-13
LU92698I2 (en) 2015-06-22
US20120178080A1 (en) 2012-07-12
CY2015017I2 (en) 2016-06-22
ZA200508298B (en) 2007-01-31
US20160081988A1 (en) 2016-03-24
EP4101846B1 (en) 2023-08-02
WO2004091502A3 (en) 2004-12-29
CA2521992C (en) 2013-02-05
US7419991B2 (en) 2008-09-02
ES2926542T3 (en) 2022-10-26
HUE055434T2 (en) 2021-11-29
EP3345895B1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
BE2013C075I2 (en)
BE2013C070I2 (en)
BE2013C067I2 (en)
BE2013C038I2 (en)
BE2013C036I2 (en)
BE2011C030I2 (en)
JP2004033749A5 (en)
BE2013C034I2 (en)
JP2004019946A5 (en)
JP2004000532A5 (en)
JP2004064073A5 (en)
JP2003288283A5 (en)
BE2012C053I2 (en)
JP2004004073A5 (en)
JP2004074396A5 (en)
JP2004140351A5 (en)
JP2004001405A5 (en)
JP2004221791A5 (en)
AU2002316235A1 (en)
AU2002255066A1 (en)
AU2002353888A1 (en)
AU2002362930A1 (en)
AU2002311957A1 (en)
ECSDI034912S (en)
JP2003293851A5 (en)